The Italian Pharmacy Market

An Emerging Institutional Asset Class

The Italian pharmacy sector has evolved into a highly attractive yet underpenetrated asset class, combining regulated stability, structural growth, and compelling risk-adjusted returns—positioning it as a unique opportunity for institutional investors seeking resilient yield in European healthcare.

Why the sector is compelling

• Structural, non-cyclical demand with demographic tailwinds
Demand is anchored in essential healthcare consumption and supported by one of Europe’s oldest populations. The rapid expansion of the “silver economy” and preventive care services further reinforces long-term growth visibility.

• Policy-driven transformation into healthcare hubs
Regulatory initiatives are actively reshaping pharmacies into integrated healthcare providers, expanding their role into diagnostics, chronic disease management, and digital health—unlocking new, higher-margin revenue streams.

• Attractive risk-return profile with downside protection
The sector benefits from historically low default rates, partial state guarantees (50–80% via the MCC Central Guarantee Fund), and yields typically exceeding Euribor +5%, offering a rare combination of resilience and premium return.

Key market insights

In 2022, the Italian Ministry of Health introduced reforms to transform pharmacies from traditional dispensaries into multifunctional healthcare hubs. This policy shift has driven both an increase in the number of pharmacies and sustained revenue growth—contrasting with markets such as Germany and the United Kingdom, where consolidation has reduced pharmacy density.

Italy has a significantly higher number of pharmacies per capita compared to Northern European countries such as the Netherlands and Denmark. This reflects their broader and more integrated role within the healthcare system, positioning pharmacies as a critical first point of care.

Over the past four years, the sector has demonstrated steady growth of approximately 3% annually, reaching €26.7 billion in total revenues. While 56% of revenues are derived from prescription medicines, the strongest growth is observed in para-pharmaceuticals, nutritional supplements, and personal care—segments benefiting from rising consumer focus on health and wellness and delivering double-digit growth.

Digitalization is highly advanced, with approximately 95% of prescriptions issued electronically (ranging from over 90% in Sardinia to nearly 98% in Sicily). This infrastructure enables pharmacies to expand into preventive services, chronic care management, and digital health solutions—improving patient outcomes while reducing pressure on hospitals.

These trends are reinforced by Italy’s demographic profile. As one of Europe’s oldest populations, the country is experiencing a structural shift toward increased healthcare consumption and long-term treatment adherence.

Credit and investment characteristics

The sector demonstrates exceptional credit resilience, supported by stable demand, regulatory oversight, and strong collateral characteristics. Pharmacy financing benefits from the MCC Central Guarantee Fund, typically covering 50–80% of exposure, significantly reducing downside risk.

Loan yields remain attractive, generally at Euribor +5% or higher, with average maturities of around seven years—providing an additional liquidity premium.

Capital is deployed across:

Market access

Specialized platforms such as TEDA Advisors provide access to this market through SME lending solutions (typically up to €1.2 million per loan), managing the full lifecycle from underwriting to servicing. These platforms also enable portfolio-level investment, allowing institutional investors to tailor exposure to their specific risk-return profiles.

Closing

The Italian pharmacy sector sits at the intersection of healthcare, demographics, and private credit, offering a differentiated opportunity with strong fundamentals, regulatory support, and scalable investment access—yet remains largely undiscovered by institutional capital.

For further information, please contact:
m.kemper@teda-advisors.com
Marco.kemper@investfair.nl